-

CEO, Jakob Lindberg, will attend the Nordic Life Science Days, 14-15 September 2016 in Stockholm Sweden.

Oncopeptides presented clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.

The results can be downloaded below.

The results further support Oncopeptides’ belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.

For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events

Silent Period

-

Interim Report Q3 2021

08:00 CET

63rd ASH Annual Meeting & Exposition

-

American Society of Hematology (ASH) 63rd annual meeting with both in-person and virtual participation at the Georgia World Congress Center in Atlanta, Georgia. ASH Annual Meeting & Exposition is the largest event in malignant and non-malignant hematology.

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-